It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
B cells have been reported to promote graft rejection through alloantibody production. However, there is growing evidence that B cells can contribute to the maintenance of tolerance. Here, we used a mouse model of MHC-class I mismatched skin transplantation to investigate the contribution of B cells to graft survival. We demonstrate that adoptive transfer of B cells prolongs skin graft survival but only when the B cells were isolated from mice housed in low sterility “conventional” (CV) facilities and not from mice housed in pathogen free facilities (SPF). However, prolongation of skin graft survival was lost when B cells were isolated from IL-10 deficient mice housed in CV facilities. The suppressive function of B cells isolated from mice housed in CV facilities correlated with an anti-inflammatory environment and with the presence of a different gut microflora compared to mice maintained in SPF facilities. Treatment of mice in the CV facility with antibiotics abrogated the regulatory capacity of B cells. Finally, we identified transitional B cells isolated from CV facilities as possessing the regulatory function. These findings demonstrate that B cells and in particular transitional B cells, can promote prolongation of graft survival, a function dependent on licensing by gut microflora.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Medical Research Council Centre for Transplantation, King’s College London, King’s Health Partners, Guy’s Hospital, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); King Abdulaziz University, Centre of Immunology, Division of Applied Medical Sciences, (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117)
2 Medical Research Council Centre for Transplantation, King’s College London, King’s Health Partners, Guy’s Hospital, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 King’s College London, Guy’s Hospital, Division of Diabetes and Nutritional Sciences, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
4 King’s College London, Guy’s Hospital, Peter Gorer Department of Immunobiology, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)